Navigation Links
Separation Reproducibility With the BioLogic Chromatography Systems

+ 1 M NaCl). All buffers were filtered and degassed prior to use. For each run on the DuoFlow system, a 50 l sample loop was overfilled with 150 l of the protein sample using an Econo gradient pump. For the BioLogic LP system, 1 ml of sample was loaded though port C of the BioLogic LP buffer selection valve. The UV detector and conductivity monitor supplied with each system were used to monitor the UV signal and conductivity, respectively. Protocol details are summarized in Tables 1 and 2 and the system components used are listed in Table 3.


Results
The BioLogic DuoFlow and BioLogic LP systems were used to successfully purify a protein test mixture with excellent reproducibility. A total of 80 ion exchange runs were performed on the BioLogic DuoFlow QuadTec system as a queue of alternating anion exchange and equilibration runs (160 runs total). As shown in Figure 1, the 80 separations were virtually indistinguishable. The observed protein retention times (Table 4) demonstrate consistent sample introduction and pump performance. The standard deviation associated with the gradient slope, 4.88 0.01 mS/cm/min, indicates excellent pump and mixer performance, which is critical for discrete protein resolution. These results confirm that the BioLogic DuoFlow chromatography system provides high run-to-run reproducibility.


On the BioLogic LP, 25 consecutive separations were performed using its Multirun feature. As shown in Figure 2, the separations were highly reproducible and exhibited extremely consistent protein elution times (Table 4). Gradient performance was also highly reproducible with a
'"/>

Source:


Page: All 1 2 3

Related biology technology :

1. Separation of 16S rRNA PCR Products From a Model Community Using Temporal Temperature Gradient Gel Electrophoresis, Rev A
2. Separation of HLA-DRB Alleles by Denaturing Gradient Gel Electrophoresis using the DCode System
3. Separation and Comparison of Proteins From Virulent and Nonvirulent Strains of the Fish Pathogen Flavobacterium psychrophilum, Using a 2-D Electrophoretic Approach
4. Separation and Quantitation of R and S Enantiomers using Normal Phase Chromatography on an API 3000 LC/MS/MS System
5. BD IMag Human Regulatory T Lymphocyte Separation Set for Isolation of Treg Cells
6. Separation of Peptides by Hydrophilic Interaction Chromatography Using TSKgel Amide-80
7. Unique Surface Treatment of Novel TSK-GEL ODS Columns Provide Separation of Aqueous and Fat Soluble Vitamins
8. Improve Recovery and Reproducibility with Pre-Treatment of Analytical TSK-GEL G3000SWXL Size Exclusion Columns
9. Rapid Chromatography Optimization by pH Scouting Using the New BioLogic Maximizer Valve System, Rev A
10. Rapid Method Development With the BioLogic DuoFlow Chromatography System for the Purification of His-Tagged Proteins
11. Purification of Murine IgG1 Using UNOsphere S and CHT Ceramic Hydroxyapatite Chromatography, Rev A
Post Your Comments:
Breaking Biology News(10 mins):Breakthrough in monitoring tropical deforestation announced in Copenhagen 2Hebrew University, American researchers show 'trigger' to stem cell differentiation 2Pathological gambling may be successfully treated with medications for substance addiction 2ClearTrial Selected to Lead Executive Panel from Pharmaceutical and Service Provider Companies at ExL Conference 13018 1ClearTrial Selected to Lead Executive Panel from Pharmaceutical and Service Provider Companies at ExL Conference 13018 2ClearTrial Selected to Lead Executive Panel from Pharmaceutical and Service Provider Companies at ExL Conference 13018 3Significant Milestone Marks the Beginning of FDA Authorized Breast Cancer Trial 13016 1Significant Milestone Marks the Beginning of FDA Authorized Breast Cancer Trial 13016 2Significant Milestone Marks the Beginning of FDA Authorized Breast Cancer Trial 13016 3Peregrine Pharmaceuticals Reports Financial Results for Fiscal Year 2009 51596 1Peregrine Pharmaceuticals Reports Financial Results for Fiscal Year 2009 51596 2Peregrine Pharmaceuticals Reports Financial Results for Fiscal Year 2009 51596 3Peregrine Pharmaceuticals Reports Financial Results for Fiscal Year 2009 51596 4Peregrine Pharmaceuticals Reports Financial Results for Fiscal Year 2009 51596 5Peregrine Pharmaceuticals Reports Financial Results for Fiscal Year 2009 51596 6Peregrine Pharmaceuticals Reports Financial Results for Fiscal Year 2009 51596 7Peregrine Pharmaceuticals Reports Financial Results for Fiscal Year 2009 51596 8Peregrine Pharmaceuticals Reports Financial Results for Fiscal Year 2009 51596 9Peregrine Pharmaceuticals Reports Financial Results for Fiscal Year 2009 51596 10Peregrine Pharmaceuticals Reports Financial Results for Fiscal Year 2009 51596 11Peregrine Pharmaceuticals Reports Financial Results for Fiscal Year 2009 51596 12Peregrine Pharmaceuticals Reports Financial Results for Fiscal Year 2009 51596 13Peregrine Pharmaceuticals Reports Financial Results for Fiscal Year 2009 51596 14Peregrine Pharmaceuticals Reports Financial Results for Fiscal Year 2009 51596 15Peregrine Pharmaceuticals Reports Financial Results for Fiscal Year 2009 51596 16Peregrine Pharmaceuticals Reports Financial Results for Fiscal Year 2009 51596 17